The DOI matches its Crossref record.
Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa
Open accessAbstract
Human sera from the United States, Thailand, and sub-Saharan Africa and chimpanzee sera were tested for neutralizing antibodies to 3 chimpanzee adenoviruses.Antibodies were more common in humans residing in sub-Saharan Africa than in humans living in the United States or Thailand.This finding suggests cross-species transmission of chimpanzee adenoviruses.V accines to HIV-1 are needed to stem further spread of the HIV pandemic.One vaccine modality that has shown promise is based on adenovirus vectors of human serotype 5 (AdHu5) (1-3).However, immune responses induced by AdHu5 vectors are reduced by preexisting AdHu5-neutralizing antibodies found in humans in the United States (4-7). The StudyTo circumvent the negative effect of preexisting immunity to common human serotypes of adenoviruses on the efficacy of adenovirus vaccine carriers, we developed vectors based on chimpanzee-derived adenoviruses C68, C6, and C1 (8).We previously showed that neutralizing antibodies to chimpanzee adenoviruses are rarely found in US residents (6).Because vaccines to HIV-1 are most urgently needed in sub-Saharan Africa, we evaluated the prevalence of neutralizing antibodies to chimpanzee adenoviruses in sera from humans residing in 3 sub-Saharan countries with natural habitats for chimpanzees: Nigeria, Cameroon, and Côte d'Ivoire.Sera from captive chimpanzees in the United States and human sera from Thailand and the United States, including samples from persons with known exposures to chimpanzees, were tested for comparison.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Dicks, M. D. J., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V. S., & Cottingham, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040385 · Cited by 384
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 300
Metadata
- Authors
- Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J.
- Venue
- Emerging Infectious Diseases
- Published
- 2006-10
- Volume
- 12
- Issue
- 10
- Pages
- 1596-1599
- ISSN
- 1080-6040 (ISSN-L)
- OpenAlex
- W2111875244
- Cited by
- 178
- References
- 0
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa. https://app.cochat.ai/papers/10.3201/eid1210.060078
- The paper
- Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J. (2006). Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa. Emerging Infectious Diseases. https://doi.org/10.3201/eid1210.060078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.